Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that the first patient has been treated in the Phase 1 study of KSI-501, an investigational bispecific antibody biopolymer conjugate targeting both VEGF and IL-6. KSI-501 is the second product candidate built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform to enter the clinic.
The Phase 1 study of KSI-501 is being conducted in the USA as an open-label, multiple ascending dose study and initially is enrolling patients with diabetic macular edema (DME). The primary objectives of the Phase 1 study are to evaluate ocular and systemic safety and to establish a maximum tolerated dose.
https://finance.yahoo.com/news/kodiak-sciences-expands-development-pipeline-113000081.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.